Researchers test drug switch to stop bone loss after osteoporosis treatment
NCT ID NCT05655013
Summary
This study aims to find the best way to switch postmenopausal women from one osteoporosis drug (denosumab) to another (zoledronate) to prevent bone loss. It will test different timing schedules for the new drug infusions over three years. The goal is to maintain bone density and strength after stopping the initial medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS, POSTMENOPAUSAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus University Hospital
Aarhus, Denmark
Conditions
Explore the condition pages connected to this study.